Current Studies
PAX-D
PAX-D is a Clinical Trial of an Investigational Medicinal Product (CTIMP). In this trial, the effects of pramipexole will be compared with placebo when added to current antidepressant medication. There is some evidence that pramipexole, a medicine already commonly used in Parkinson’s disease, may be an effective treatment for people with treatment resistant depression. The trial will look at effectiveness in the short-term (after 12 weeks treatment) and in the longer-term (48 weeks). The trial will also assess the side effects of pramipexole and explore patients’ experience of taking it. Find out more: paxd.web.ox.ac.uk.
Past Studies
LQD Study: https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-017-1393-0
ATP Study: https://cctu.org.uk/portfolio/core/trials-closed/atp
Publications
2023
Halahakoon, D.C., Kaltenboeck, A., … , Browning, M. (in press) Pramipexole Enhances Reward Learning by Preserving Value Estimates. Biological Psychiatry
DOI: 10.1016/j.biopsych.2023.05.023
Jauhar, S., Cowen, P. J., & Browning, M. (2023). Fifty years on: Serotonin and depression. Journal of Psychopharmacology (Oxford, England), 2698811231161813.
DOI: 10.1177/02698811231161813
2022
Chapman, N., Browning, M., …, Mansoori, P. (in press) Setting national research priorities for Difficult-to-Treat Depression in the UK between 2021-2026. Journal of Global Health
DOI: 10.7189/jogh.12.09004
Kaltenboeck, A., Halahakoon, D. C., Harmer, C. J., Cowen, P., & Browning, M. (2022). Enhanced taste recognition following subacute treatment with the dopamine D2/D3 receptor agonist pramipexole in healthy volunteers. The International Journal of Neuropsychopharmacology
DOI: 10.1093/ijnp/pyac030
Au-Yeung, S., …, Browning, M. (2022) PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression. Evidence Based Mental Health 25(2).
DOI: 10.1136/ebmental-2021-300282
2021
Browning, M., … Dawson, G. R. (2021). The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): An open-label, randomised controlled trial. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 46(7), 1307–1314.
DOI: 10.1038/s41386-021-00981-z
Find out more about our research
To find out more about our research at the Department of Psychiatry, University of Oxford, please visit: https://www.psych.ox.ac.uk/research/computational-psychiatry
